Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to the fourth quarter and full year 2025 Harvard Bioscience Earnings Conference Call. All participants will be in a listen-only mode. After today's presentation, there will be a question and answer session. Instructions will be given at that time. Please note this event is being recorded. I would like to turn the conference over to Taylor Krafcik, Senior Vice President at Ellipsis TA. Please go ahead. Thank you, Operator, and good morning, everyone. Thank you for joining the Harvard Bioscience fourth quarter and full year 2025 earnings conference call. Leading the call today will be John Duke, President and Chief Executive Officer, and Mark Frost, Chief Financial Officer. In conjunction with today's call, we've provided a presentation that will be referenced during our remarks that is posted to the investor relations section of our website at investor.harvardbioscience.com. Please note that statements made in today's discussion that are not historical facts, including statements on management, Expectations of future events or future financial performance are forward-looking statements and are made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current views of Harvard Bioscience Management, and Harvard Bioscience assumes no obligation to update or revise any forward-looking statements. Actual results may differ materially from those expressed or implied. Please refer to today's press release, the Harvard Bioscience Form 10-K, which we expect will be filed. within 24 hours of this call, and other filings with the Securities Exchange Commission for additional disclosures on forward-looking statements and the risks, uncertainties, and contingencies associated t...